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Micronuclei are small membrane-enclosed 
cytoplasmic bodies containing whole or frag-
mented chromosomes, which are formed 
during anaphase in aberrant mitosis and in 
response to genotoxic stress. in the latter 
scenario, the formation of micronuclei can be 
used to assess the toxicity of various chemicals 
and drugs. A report by Rello-varona et al. in 
a previous issue describes the elimination of 
micronuclei by autophagy.1
Macroautophagy (hereafter referred to 
as autophagy) is a highly regulated cellu-
lar mechanism for degradation and recycling 
of cytoplasmic contents. This process begins 
with the formation of an autophagosome, 
a double membrane structure that engulfs 
parts of the cytosol and whole organelles, 
finally fusing with a lysosome to allow the 
degradation of the enclosed material. The 
final products, including amino acids, lipids 
and nucleotides, are released into the cyto-
sol via permeases present at the lysosomal 
membrane and can then be used for ana-
bolic reactions to maintain cellular functions. 
Autophagy is conserved from yeast to human 
and is regulated by the Atg family of proteins.2 
Autophagy is a general response to cellular 
stress, which mediates the clearance of dan-
gerous cell components, such as damaged 
mitochondria, and intracellular pathogens, 
such as viral particles and bacteria.3
The study by Rello-varona and colleagues 
demonstrates that micronuclei generated 
after cell cycle perturbations are surrounded 
by LC3- and p62-positive staining (Fig. 1). This 
phenomenon appears to be dependent on 
the autophagy regulators Atg7 and Atg5, as 
it is not observed in cells treated with siRnAs 
for Atg5 and Atg7. importantly, these micro-
nuclei contain a reduced quantity of DnA, as 
determined by DnA binding dyes and fluo-
rescent histone tagging, and exhibit a discon-
tinuous membrane, suggesting that both the 
Cell Cycle News & Views
Micronucleophagy: A new mechanism to protect against  
chromosomal instability?
Comment on: Rello-Varona S, et al. Cell Cycle 2012; 11:170–6; PMID:22185757;  
http://dx.doi.org/10.4161/cc.11.1.18564
Patricia Boya1 and Patrice Codogno2; 1CIB; Consejo Superior de Investigaciones Cientificas (CSIC); Madrid, Spain; 2INSERM U984; University Paris-Sud 11; 
Châtenay-Malabry, France; *Email: pboya@cib.csic.es and patrice.codogno@u-psud.fr; http://dx.doi.org/10.4161/cc.11.4.19278
nuclear membrane and DnA are degraded by 
autophagy. As expected, these structures were 
also positive for the lysosomal marker Lamp2. 
interestingly, only micronuclei presenting 
symptoms of DnA damage were targeted, as 
indicated by labeling with phospho-γH2AX, a 
marker of DnA damage.1
selective autophagy of organelles (e.g., 
mitochondria) and intracellular pathogens 
requires the recognition of LC3-interacting 
regions in target proteins at the surface 
of organelles and intracellular bacteria.4 
interestingly, Rello et al. report that micro-
nuclei were also positive for p62, an LC3-
interacting protein,5 whereas no p62 staining 
was detected in LC3-negative micronuclei. it 
remains to be determined whether p62 rep-
resents the bona fide receptor for this new 
form of selective autophagy or micronucle-
ophagy. Moreover, further studies are required 
to determine how DnA damage promotes 
LC3 recognition, leading to the elimination of 
potentially harmful cellular structures.
Degradation of nuclear-derived material 
and even entire nuclei by autophagy has been 
previously described in non-vertebrates. in 
fact, several studies have shown that part of 
the nucleus can be removed by piecemeal 
microautophagy of the nucleus,6 so called 
because no vesicular membrane-bound inter-
mediates are created. Furthermore, in syncytial 
fungi the entire nucleus can be degraded by 
autophagy. it thus seems plausible that the 
size of the material undergoing degradation 
does not limit the nuclear degradation pro-
cess. indeed, giant LC3-positive structures are 
observed when S. aureus invades mammalian 
cells.7 selectivity, rather than the target size, 
thus appears to be the most important aspect 
of this process.
Autophagy plays an important role in limit-
ing DnA damage and genomic instability; 8 
the relevance of the findings of Rello-varona 
to these processes remains to be determined. 
Further investigation of these phenomena, 
both in tumors and in autophagy-deficient 
cells in vivo, is thus required to determine 
whether micronucleophagy may be used to 
limit the consequences of chromosomal insta-
bility. This new form of selective autophagy 
adds yet more intracellular structures and 
organelles to the growing list of cellular com-
ponents that are specifically targeted for lyso-
somal degradation.
Figure 1. schematic representation of markers during micronucleophagy.
© 2012 Landes Bioscience.
Do not distribute.
646 Cell Cycle volume 11 issue 4
References
1. Rello-varona s, et al. Cell Cycle 2012; 11:170-6; 
PMiD:22185757; http://dx.doi.org/10.4161/
cc.11.1.18564.
2. yang Z, et al. Curr Opin Cell Biol 2010; 22:124-
31; PMiD:20034776; http://dx.doi.org/10.1016/j.
ceb.2009.11.014.
3. Kroemer G, et al. Mol Cell 2010; 40:280-93; 
PMiD:20965422; http://dx.doi.org/10.1016/j.mol-
cel.2010.09.023.
4. Dikic i, et al. Cancer Res 2010; 70:3431-4; 
PMiD:20424122; http://dx.doi.org/10.1158/0008-
5472.CAn-09-4027.
All p65-containing dimers are not equal
Comment on: Mora E, et al. Cell Cycle 2012; 11:159–69; PMID:22189654;  
http://dx.doi.org/10.4161/cc.11.1.18559
Simona Saccani; Max Planck Institute for Immunobiology and Epigenetics; Freiburg, Germany; Email: saccani@immunbio.mpg.de;  
http://dx.doi.org/10.4161/cc.11.4.19279
Animals have evolved a strategic set of 
responses to control and react against infec-
tion by pathogens and tissue injury, which, 
together, comprise the process of inflamma-
tion.1 inflammation is initially a beneficial 
reaction for the host; however, if prolonged, 
becoming chronic inflammation, it can be 
detrimental and lead to the development or 
aggravation of several pathologies, including 
cancer.1,2 These harmful effects of the inflam-
matory response have attracted considerable 
attention in therapeutic drug generation.
As a result, much effort has been directed 
at blocking the activity of one of the central 
players in inflammation: nFκB.1-3 nFκB is an 
evolutionarily-conserved family of transcrip-
tion factors that plays a crucial role in innate 
immunity by driving the expression of a vari-
ety of inflammatory mediators, such as cyto-
kines and chemokines, and genes involved in 
pro-survival and anti-apoptotic signaling.3
A prolonged or persistent activation of 
nFκB can be harmful for an organism, yet it 
mediates multiple functions that are vital for 
health and host defense.1-3 As a corollary, a 
complete block of nFκB activity would not 
be always advantageous. An attempt to solve 
this issue has been to identify drugs which 
selectively act only on specific downstream 
nFκB targets.2
Most nFκB targets are activated in a cell-
type and stimulus-specific fashion.3 nFκBs act 
in the form of homo- and heterodimers and, 
in some cases, target genes are activated only 
by particular dimer combinations, whereas 
others are activated redundantly by multiple 
different dimers.3,4 each nFκB dimer binds 
to a 9–10bp DnA motif (the “kb site”), which 
represents the first level of target specificity.3,4 
However, although in vitro most dimers bind 
to all kb sites with high affinity, it is increas-
ingly evident that in vivo, the various dimers 
display different abilities to bind to particular 
kb sites: the rules which constrain this are 
under active investigation but are still not 
completely clear. subsequent transcriptional 
activation of target genes by nFκB is also 
the result of multiple levels of integrated 
regulation, including nucleosome positioning 
at the target site, the effects of permissive/
repressive histone modifications and post-
translational modifications to nFκB itself.3-6 
in particular, it has been shown that phos-
phorylation of the nFκB subunit p65 at dif-
ferent residues has a series of transcriptional 
effects.4,5,7 in keeping with current efforts to 
characterize drugs capable of targeting only 
certain aspects of nFκB activity, Mora et al.8 
showed, in a previous issue of Cell Cycle, that 
Bindarit, a proven anti-inflammatory drug, tar-
gets a specific pool of p65-containing dimers 
in activated macrophages. Bindarit has been 
in use for some years and is known to inter-
fere with monocyte recruitment during early 
inflammatory responses by regulating pro-
duction of the chemokine MCP1.9 They have 
now shown that Bindarit causes a partial 
block in iκBα phosphorylation, p65 nuclear 
entry and its phosphorylation at s536. This 
results in a decrease in the transcriptional 
activation of MCP18 together with a handful 
of other inflammatory genes.
importantly, many other nFκB target 
genes are unaffected by treatment with 
Bindarit. This highlights the importance of 
targeting specific facets of nFκB and also 
reveals that the decrease (but not elimination) 
of nuclear p65 and, in particular, of the s536-
phosphorylated form, differentially affects its 
binding to particular kb sites at target genes. 
Thus, Bindarit seems to regulate inflammation 
by selectively modulating the activation of a 
subset of chemokines and, in so doing, reduc-
ing amplification of inflammation without 
eliminating it.8
while this work provides a first, fascinating 
glimpse of how Bindarit controls the activa-
tion of MCP1 (along with several other tar-
get genes), it raises some new, unanswered 
questions. Additional studies will be needed 
in order to identify the effector molecule(s) 
responsible for the reduced activation of 
p65-containing dimers (one possibility is that 
Bindarit may be acting as an inhibitor of iKKβ, 
which is known to phosphorylate both ikBα 
and p655) and the extent to which Bindarit 
affects the activity of other nFκB dimers.
in the future, it is likely that increasing 
attention will be focused on developing 
drugs which, like Bindarit, control specific 
subsets of nFκB targets without disrupting 
the entire inflammatory system. Other areas 
which may be interrogated as possible drug 
targets include the various other post-trans-
lational modifications of the nFκB subunits 
as well as aspects of chromatin structure that-
may discriminate specific subsets of target 
genes.1,2,6,8
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Desensitization of nociceptive neurons to cap-
saicin has a clear analgesic potential. indeed, a 
high concentration capsaicin patch is already 
in clinical use to relieve neuropathic pain. The 
cloning of the capsaicin receptor TRPv1 has 
spurred considerable efforts in the pharma-
ceutical industry to find potent, small-mol-
ecule TRPv1 antagonists.1 However, adverse 
effects have so far prevented any TRPv1 antag-
onists from advancing beyond phase ii trials. 
in particular, concerns have surfaced around 
the effects of antagonizing TRPv1 on thermo-
regulation (hyperthermia) and on the ability to 
detect noxious heat (risk for scalding injury).1 
in a previous issue, Romanovsky and cowork-
ers raised the possibility that TRPv1 blockade 
might also affect the response to sepsis, espe-
cially in older hosts.2
This is concerning, because both systemic 
inflammatory response syndrome (siRs), 
which can occur following tissue damage, and 
sepsis, which occurs with microbial infection, 
are major public health problems and cause 
thousands of deaths every year.3,4 in addition, 
despite extensive research into the inflamma-
tory cascade triggered during siRs and sepsis, 
the field has witnessed many failed clinical 
trials with drugs that alter the inflammatory 
response.3 That some anti-inflammatory drugs 
lacked beneficial effects while others were 
harmful attests to the complexity and to the 
potential hazard of perturbing the inflamma-
tory response.
Researchers have shown that the inflam-
matory response is modulated by a num-
ber of humoral and neural processes. 
Among the neural processes, the cholinergic 
anti-inflammatory pathway is long recog-
nized.5 More recently, TRPv1-expressing 
sensory neurons have emerged as poten-
tial players in modulating the inflammatory 
response during siRs and sepsis. But how 
can TRPv1-expressing neurons play a role in 
inflammation? These neurons are known to 
release neuropeptides (e.g., substance P and 
calcitonin gene-related peptide) that initiate 
the cascade of neurogenic inflammation.1 
indeed, TRPv1 blockade decreases neurogenic 
inflammation.6
Recent studies demonstrate that during 
LPs-induced siRs in mice, TRPv1 deficiency 
is associated with increased inflammatory 
mediators and exacerbated organ damage.7 
Moreover, pharmacological TRPv1 blockade 
decreases survival.8 However, the effect of 
TRPv1 actually varies depending on the insult 
(sepsis or LPs) and the mode of receptor block-
ade (desensitization, antagonism or gene dis-
ruption). in mice, both genetic deletion of 
TRPv1 and its desensitization to the ultrapo-
tent agonist resiniferatoxin worsen survival 
and decrease bacterial clearance during poly-
microbial sepsis but were without significant 
effect when LPs (without infection) triggered 
the inflammatory response.8
studies with the relatively non-selective 
TRPv1 antagonist, capsazepine, yielded con-
flicting results. in mice with LPs-induced 
siRs, capsazepine worsened survival.8 By con-
trast, when administered before the onset 
of infection and sepsis, capsazepine actually 
improved survival.9 Clearly, the role of TRPv1-
expressing sensory neurons in siRs and sepsis 
is incompletely understood, and the net effect 
of TRPv1 disruption seems to vary depending 
on the insult and the mode of disruption.
An underrecognized factor in TRPv1 
actions is aging. For example, compared with 
their wild-type littermates, Trpv1-knockout 
mice are leaner when they are young but are 
more obese when they are getting old.1
Using a potent and selective TRPv1 antag-
onist, AMG517, Romanovsky suggests that 
aging may also alter the role of TRPv1 in LPs-
induced siRs.2 while some might question 
the statistical power of some experiments, 
they confirm previous findings with capsaz-
epine in young animals that TRPv1 antago-
nism worsens survival after LPs challenge. 
surprisingly, this effect is reversed in older 
mice where AMG517 improves survival. These 
findings suggest that during LPs-induced siRs, 
the role of TRPv1 might reverse with aging 
from anti-inflammatory to pro-inflammatory. 
Conversely, in the setting of infection, older 
TRPv1-deficient animals die earlier than con-
trols, similar to findings previously reported in 
younger septic mice.8
in conclusion, aging seems to reverse the 
role of TRPv1 from anti-inflammatory to pro-
inflammatory during siRs but not sepsis. This 
is supported by the decreased serum levels 
of tumor necrosis factor, a known pro-inflam-
matory mediator, in LPs-challenged Trpv1-
knockout older mice.2 while it is tempting to 
categorize TRPv1 as anti-inflammatory vs. pro-
inflammatory, one might argue that the inflam-
matory response in siRs and sepsis is complex, 
and the presented data are far from being 
conclusive. Despite these issues, this is an 
important contribution to our understanding 
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of the role of TRPv1 in inflammatory response. 
indeed, since TRPv1 blockade has been used 
clinically,1 there is a real need to investigate 
the mechanisms involved more deeply. should 
we be nervous? At a minimum, we should be 
vigilant.
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Despite the growing number of functions 
assigned, ranging from pigmentation to fertil-
ity, the main role of the tumor suppressor pro-
tein p53 remains to preserve genome integrity 
by controlling two key biological outcomes 
of genome perturbation: the induction of cell 
cycle arrest, allowing DnA repair or, when 
the damage is irreparable, the induction of 
programmed cell death.1 The choice between 
cell cycle arrest and apoptosis is influenced by 
different p53-dependent transcriptional pro-
grams that either involve cyclin-dependent 
kinase inhibitors (such as p21/wAF1) or apop-
totic genes, such as p53AiP1, nOXA and Bax.2
How the decision is made at the molecu-
lar level is still the focus of intense research 
efforts, but it is clear that p53 post-transla-
tional modifications are key determinants of 
this decision: p53 phosphorylation on ser-15 
and ser-20 residues is associated with cell 
cycle arrest, while ser-46 phosphorylation is 
linked to cell death.3 Protein acetylation at 
defined residues was also associated to the 
activation of apoptotic genes by p53. More 
recently, p53 ubiquitination, was found to 
affect, under certain conditions, the activity 
of p53 rather than stability. Ubiquitinated p53 
was found in complexes bound to cell cycle 
arrest but not apoptosis genes, suggesting 
that p53 ubiquitination contributes to the 
selection of its transcriptional targets.4 p53 
ubiquitination is influenced by a plethora of 
ubiquitin ligases, most of them characterized 
for their ability to flag p53 for proteasome-
mediated degradation.5
Among these, recent studies have indicated 
that some members of the tripartite motif 
(TRiM) proteins (one of the subfamilies of the 
RinG type e3 ubiquitin ligases), which function 
as important regulators for carcinogenesis, are 
downregulated in tumors and act as important 
p53 regulators.6 The RinG domain of TRiM24 
functions as an e3-ubiquitin ligase that targets 
p53 for degradation, and its depletion induces 
p53-dependent apoptosis.7 The promyelocytic 
leukemia protein PML/TRiM19 is a p53 target 
that facilitates p53-Thr18 phosphorylation in 
response to DnA damage by recruiting p53 
into PML nuclear bodies, thereby leading to 
p53 activation by protecting it from MDM2 
inhibition. More recently, the ataxia telangiec-
tasia group D-complementing ATDC/TRiM29 
protein has been shown to bind and antago-
nize p53-mediated functions.6
in a very interesting article appeared in 
a previous issue of Cell Cycle, Caratozzolo 
and colleagues8 identified in the e3 ubiqui-
tin ligase TRiM8 as a key regulator of p53 in 
the cell cycle arrest vs. apoptosis decision. 
They showed that p53 directly activates TRiM8 
transcription after DnA damage through a 
p53-responsive element in the first intron of 
TRiM8 gene. Once upregulated by p53, TRiM8 
directly interacts with p53, inducing its stabili-
zation by inhibiting MDM2 binding and, most 
interestingly, activating the cell cycle arrest 
transcriptional program but not apoptosis. This 
is accompanied by an increase of ser-15 and 
ser-20 phosphorylated p53 level but not of 
ser-46, and, indeed, selective TRiM8 deple-
tion facilitates DnA damage-induced apopto-
sis. exogenous TRiM8 expression induced cell 
cycle arrest only in cell lines harboring wild-
type p53 and had no effect in p53-null cells, 
indicating that TRiM8-induced cell cycle arrest 
is p53-dependent.
These findings highlight the importance 
of a novel feedback loop regulating the 
p53-dependent transcriptional program acti-
vated by DnA damage. naturally, the findings 
of Caratozzolo et al. also generate questions. 
How does TRiM8 affect p53 ubiquitination? 
How are TRiM8 binding and p53 phosphoryla-
tion interconnected? which comes first? Does 
TRiM8 also affect p53 acetylation? Are the 
other p53 family members involved in this 
feedback loop?
Future studies will certainly help address 
some of these questions and enhance our 
understanding of p53-related network, the 
ultimate beneficiaries being cancer-afflicted 
patients and their families.
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High-fidelity chromosome segregation dur-
ing both mitosis and meiosis is essential for 
the propagation and inheritance of stable 
genomes. Defects in these fundamental pro-
cesses promote aberrant chromosome seg-
regation, which, in the absence of cell death, 
produces aneuploid progeny. in somatic cells, 
aneuploidy is a putative cancer-promoting 
event. in germ cells, aneuploidy can reduce 
reproductive fertility and promote the accu-
mulation of trisomies, such as those associated 
with Down, Patau or edward syndromes. in 
order for maintenance of genomic integrity, 
cells have an elaborate network of proteins 
that function during mitosis and meiosis to 
ensure accurate chromosome segregation. 
One such proposed mitotic regulator is shu-
goshin. whereas budding yeast and Drosophila 
contain a single shugoshin gene, fission yeast 
and mammals have two paralogs (sgo1 and 
sgo2). The exact role of the shugoshin fam-
ily of proteins during mitosis and meiosis 
has been somewhat elusive. several func-
tions have been proposed for sgo1, includ-
ing protecting centromeric cohesion through 
associating with PP2A phosphatase,1 ensuring 
attachment error correction through chromo-
some passenger complex positioning,2 main-
taining centriole cohesion3 and mediating 
kinetochore microtubule attachment by inter-
acting directly with spindle microtubules.4 Like 
sgo1, sgo2 has also been similarly implicated 
in centromeric cohesion and attachment error 
correction, although under different cellular 
circumstances than sgo1. On the other hand, 
sgo2, but not sgo1, is thought to function 
during mitosis through binding spindle micro-
tubules through its association with astrin5 and 
through binding Mad2.6 Until now, the physi-
ological consequences of deregulated sgo1 
had been unknown.
in a previous issue of Cell Cycle, yamada and 
colleagues set out to assess the cellular and 
physiological consequences of reduced sgo1 
expression,7 since mouse sgo1 encodes an 
essential gene. importantly, which functions of 
sgo1 are required for cell viability and whether 
this occurs at centromeres or centrosomes 
remains unknown. One hint that centromeric, 
mitotic sgo1 may not be required for viability, 
however, comes from the observation that 
interphase sgo1 is sufficient for the establish-
ment of centromeric cohesion.8 This raises the 
question of what the function of mitotic sgo1 
is, in addition to whether and how it contrib-
utes to chromosome segregation. Consistent 
with the reported roles of sgo1, mouse embry-
onic fibroblasts haploinsufficient for sgo1 har-
bored both amplified centrosomes as well as 
chromosomes that were improperly attached 
to spindle microtubules. whether the attach-
ment defect was due to aberrant geometries 
from centrosome amplification,9 reduced cor-
rection of defective kinetochore microtubule 
interactions or precocious separation of sister 
chromatids is not known.
Because diminished sgo1 expression had 
been previously linked to human colon neo-
plastic lesions, yamada and colleagues chal-
lenged sgo1 heterozygous mice with AOM, 
a carcinogen that generates DnA damage 
to initiate colon carcinogenesis. importantly, 
mice heterozygous for sgo1 harbored 5-fold 
more colon adenomas than wild-type mice at 
12 weeks after completion of AOM treatment. 
Rather intriguingly, mice haploinsufficient for 
sgo1 were actually more prone to cell death in 
the colonic mucosa compared with wild-type 
mice, at least in the initial phase of the experi-
ment. This is a first demonstration of enhanced 
cell death following carcinogen challenge in 
a chromosomally unstable murine model. 
However, it remains an open question how 
enhanced cell death, although only immedi-
ately following carcinogen challenge, might 
alter the delicate balance regulating cell pro-
liferation vs. cell death to influence tumor 
progression. This relationship could have sig-
nificant implications in tumor etiology, pro-
gression and aggressiveness.
in summary, this study provides a causal 
link between diminished sgo1 expression 
and induction of carcinogen-induced colon 
tumorigenesis. Additionally, these experi-
ments raise a number of intriguing questions 
concerning the molecular mechanism for how 
sgo1 contributes to high-fidelity chromosome 
segregation. The study of sgo1 in mammals 
continues the line of investigation that began 
with the study of a single shugoshin gene 
in budding yeast and will likely lead to an 
increased understanding of the multiple layers 
of regulation necessary for proper chromo-
some segregation.
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Centrosome amplification and aneuploidy 
are commonly observed features of cancer 
cells. whether these defects are a cause or 
a consequence of cancer development has 
been a subject of intense recent research. The 
generation of multiple knockout mouse mod-
els for genes involved in the spindle check-
point, kinetochore-microtubule attachment or 
mitotic exit has provided strong evidence link-
ing mitotic defects to chromosome instability 
and tumorigenesis.1 Loss-of-function muta-
tions of these mitotic regulators are, however, 
rarely found in tumor samples from human 
patients, suggesting that the chromosome 
instability observed in most tumors is due to 
defects in other processes. Recently, genomic 
studies using patient samples have implicated 
genes involved in chromosome cohesion as 
a likely source of chromosome instability in 
tumors.2,3
Chromosome cohesion is established 
during DnA replication in s phase and is 
required to keep the two sister chromatids 
together until anaphase, when the sister chro-
matids are segregated into the two daugh-
ter cells. Central to the cohesion process are 
the cohesin complex (which is composed of 
smc1, smc3, scc1, and sA1/2) and multiple 
cohesin regulators that load (scc2-scc4), sta-
bilize (esco1/2 and sororin), protect (sgo1) 
or remove (wapl and separase) cohesin from 
chromosomes during the proper stages of the 
cell cycle. Most cohesin on chromosome arms 
is removed during early mitosis by mitotic 
kinases and wapl. A small of pool of cohesin 
at the centromeres is protected by the com-
plex between shugoshin (sgo1) and PP2A.4,5 
This centromeric pool of cohesin is cleaved 
by separase following the biorientation of 
all sister chromatids and the silencing of the 
spindle checkpoint. inactivation of sgo1 leads 
to premature sister-chromatid separation in 
cultured human cells.4,5
Mutations of multiple components of the 
cohesion pathway, including smc1, smc3 and 
sA2 were found in human cancers.2,3 However, 
whether mutations of cohesin and its regu-
lators directly contributed to chromosome 
instability and tumorigenesis remained to be 
tested. The work by yamada and coworkers in 
a previous issue of Cell Cycle shed light on this 
matter.6 By generating sgo- knockout mice, the 
authors were able to test whether reduction in 
sgo1 levels resulted in chromosome instability 
and tumor formation. As expected, due to the 
key role of sgo1 in cohesion protection, homo-
zygous sgo1-knockout mice were embryonic 
lethal. However, heterozygous sgo1+/− mice 
were viable, and cells from these mice showed 
an increase in chromosome segregation 
defects, including chromosome misalignment, 
lagging chromosomes and the formation of 
anaphase bridges. Ultimately, these defects 
led to an increase in the number of aneuploid 
and polyploid cells, indicating that sgo1 muta-
tions were sufficient to cause chromosome 
instability. Most importantly, sgo1+/− mice 
showed a 5-fold increase in the formation of 
colon tumors when challenged with a carcino-
gen, establishing a direct link between sgo1 
haploinsufficiency and increased tumorigenic 
potential.
Another phenotype observed by yamada 
and colleagues in sgo1+/− cells was centro-
some amplification. Prior studies had impli-
cated a short splice variant of sgo1 (ssgo1), 
cohesin, and separase in regulating the centro-
some cycle.7-9 Thus, different splicing variants 
of sgo1 appear to have specific roles at the 
centromeres and the centrosomes. selective 
complementation of sgo1+/− cells that are defi-
cient for both splicing isoforms will determine 
the specific cellular functions of each iso-
form. More importantly, complementation of 
sgo1+/− mice with different sgo1 isoforms will 
reveal the individual contributions of cohesion 
defects and centrosome amplification to can-
cer development.
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